HBM Healthcare Investments AG

HBM Healthcare Investments publishes Quarterly Report as at 30 June 2024 with key figures for the first three months of the 2024/2025 financial year

Key Figures 15.7.2024

Key Figures 30.06.2024

Shareholders’ Meeting of HBM Healthcare Investments approved all proposals by the Board of Directors

Key Figures 15.06.2024

Key Figures 31.05.2024

HBM portfolio company Yellow Jersey Therapeutics to be acquired for USD 1.25 billion

HBM Healthcare Investments’ portfolio company Swixx BioPharma boosts sales and profits through strategic acquisition in Latin America

HBM Healthcare Investments’ portfolio company Swixx BioPharma boosts sales and profits through strategic acquisition in Latin America

Key Figures 15.05.2024

HBM Healthcare Investments achieves a balanced result in the 2023/2024 financial year

Key Figures 30.04.2024

Key Figures 15.04.2024

Key Figures 31.03.2024

HBM Healthcare Investments publishes net asset value per share (NAV) of CHF 248.10 as at 31 March 2024 and quarterly profit of CHF 156 million

Key Figures 15.03.2024

Key Figures 29.02.2024

Key Figures 15.02.2024

Key Figures 31.01.2024

HBM Healthcare Investments publishes Quarterly Report as at 31 December 2023 with key figures for the first nine months of the 2023/2024 financial year

Key Figures 15.01.2024

HBM Healthcare Investments publishes net asset value per share (NAV) of CHF 225.03 as at 31 December 2023

Key Figures 31.12.2023

Key Figures 15.12.2023

Key Figures 30.11.2023

AbbVie to acquire HBM portfolio company ImmunoGen for USD 10.1 billion in cash

Key Figures 15.11.2023

Key Figures 31.10.2023

Key Figures 15.10.2023

HBM Healthcare Investments activates share buyback programme